PBAC Public Summary Documents – July 2024
Page last updated: 15 November 2024
Public Summary Documents relating to the July 2024 PBAC meeting.
- Adalimumab; Injection 20 mg in 0.2 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled pen, Injection 80 mg 0.8 mL pre-filled syringe, Injection 80 mg in 0.8 mL pre-filled pen; Hyrimoz®
- Adrenaline (Epinephrine); I.M. injection 150 micrograms in 0.15 mL (as acid tartrate) single dose syringe auto injector, I.M. injection 300 micrograms in 0.3 mL (as acid tartrate) single dose syringe auto injector; Jext®, Jnr, Jext®
- Apalutamide; Tablet 240 mg; Erlyand®
- Belzutifan; Tablet 40 mg; Welireg®
- Dienogest; Tablet 2 mg; Visanne®
- Drospirenone with Ethinylestradiol; Pack containing 24 tablets 3 mg drospirenone with 20 micrograms ethinylestradiol (as betadex clathrate) and 4 inert tablets; Yaz®; Pack containing 21 tablets 3 mg drospirenone with 30 micrograms ethinylestradiol and 7 inert tablets; Yasmin®
- Dupilumab; Injection 200 mg in 1.14 mL single dose pre filled syringe, Injection 300 mg in 2 mL single dose pre filled syringe; Dupixent®
- Elranatamab; Solution for subcutaneous injection 44 mg in 1.1 mL (40 mg per mL), Solution for subcutaneous injection 76 mg in 1.9 mL (40 mg per mL); Elrexfio®
- Esketamine; Nasal spray solution 28 mg in 0.2 mL (2 actuations); Spravato®
- Estradiol; Transdermal gel 500 micrograms (as hemihydrate) in 0.5 g sachet; Sandrena®
- Faricimab; Solution for intravitreal injection 28.8 mg in 0.24 mL (120 mg per mL); Vabysmo®
- Iptacopan; Capsule 200 mg; Fabhalta®
- Ivosidenib; Tablet 250 mg; Tibsovo®
- Lanreotide; Injection 60 mg (as acetate) in single dose pre-filled syringe, Injection 90 mg (as acetate) in single dose pre-filled syringe, Injection 120 mg (as acetate) in single dose pre-filled syringe; Somatuline® Autogel
- Levodopa with Carbidopa and Entacapone; Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg and with entacapone 20 mg per mL, 47 mL; Lecigon®
- Linzagolix; Tablet 100 mg (as choline), Tablet 200 mg (as choline); Yselty®
- Methotrexate; Tablet 2.5 mg (as sodium), Tablet 10 mg (as sodium); Methoblastin®
- Milk Powder -Synthetic; Low calcium oral powder 400 g (Locasol); Locasol®
- Morphine; Tablet containing morphine sulfate pentahydrate 30 mg; Anamorph®
- Nirsevimab; Solution for injection 50 mg in 0.5 mL pre‑filled syringe, Solution for injection 100 mg in 1 mL pre‑filled syringe; Beyfortus®
- Nivolumab; Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®; Ipilimumab; Injection concentrate for I.V. infusion 50 mg in 10 mL; Yervoy®
- Odevixibat; Capsule 200 micrograms, Capsule 400 micrograms, Capsule 600 micrograms, Capsule 1200 micrograms; Bylvay®
- Olaparib; Tablet 100 mg, Tablet 150 mg; Lynparza®
- Prasugrel; Tablet 5 mg, Tablet 10 mg; Prasugrel SCP
- Progesterone; Capsule 300 mg; Utrogestan®
- Propylene Glycol; Eye drops 60 micrograms per mL, 10 mL; Systane Balance®
- Ravulizumab; Solution concentrate for I.V. infusion 300 mg in 3 mL, Solution concentrate for I.V. infusion 1,100 mg in 11 mL; Ultomiris®
- Respiratory Syncytial Virus Vaccine; Powder and suspension for injection (0.5 mL); Arexvy®
- Risdiplam; Powder for oral solution 750 micrograms per mL, 80 mL; Evrysdi®
- Selpercatinib; Capsule 40 mg, Capsule 80 mg; Retevmo®
- Talazoparib; Capsule 0.1 mg, Capsule 0.25 mg, Capsule 0.35 mg, Capsule 0.5 mg; Talzenna®
- Vedolizumab; Powder for injection 300 mg; Entyvio®
- Zanubrutinib; Capsule 80 mg; Brukinsa®
- Zilucoplan; Solution for injection 16.6 mg in 0.416 mL (as tetrasodium) pre-filled syringe Solution for injection 23 mg in 0.574 mL (as tetrasodium) pre-filled syringe, Solution for injection 32.4 mg in 0.810 mL (as tetrasodium) pre-filled syringe; Zilbrysq®
The following Public Summary Document was finalised out-of-session between March 2024 and July 2024 meetings
The following Public Summary Documents have been updated:
November 2023 PBAC meeting
- Midazolam: Oromucosal solution in pre-filled syringe 2.5 mg in 0.25 mL, Oromucosal solution in pre-filled syringe 5 mg in 0.5 mL, Oromucosal solution in pre-filled syringe 7.5 mg in 0.75 mL, Oromucosal solution in pre-filled syringe 10 mg in 1 mL; Zyamis®
